The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer
Extreme heterogeneity of breast cancer (BC) is considered to be one of the reasons that affects the success of treatment. According to current classifications, there are 4 molecular subtypes (MS). The basis for subtypes division is immunohistochemical testing of tumor cell receptors - estrogen (ER),...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dnipro State Medical University
2016-05-01
|
| Series: | Medičnì Perspektivi |
| Subjects: | |
| Online Access: | http://medpers.dsma.dp.ua/issues/2016/N2/81-86.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846143895127195648 |
|---|---|
| author | Bondarenko I.N. Elhajj Mohammad H. Chebanov K.O. Phokhach A.V. Bondarenko Y.N. |
| author_facet | Bondarenko I.N. Elhajj Mohammad H. Chebanov K.O. Phokhach A.V. Bondarenko Y.N. |
| author_sort | Bondarenko I.N. |
| collection | DOAJ |
| description | Extreme heterogeneity of breast cancer (BC) is considered to be one of the reasons that affects the success of treatment. According to current classifications, there are 4 molecular subtypes (MS). The basis for subtypes division is immunohistochemical testing of tumor cell receptors - estrogen (ER), progesterone (PR), HER2-neu and Ki-67. The doctrine of the tumor MS was the basis for the individualization of therapeutic tactics in patients with breast cancer. It was studied that luminal A subtype is the most common and the most favorable, with hormone therapy being a highly effective treatment method. Luminal B subtype, HER2 - positive and triple negative MS is characterized by a high aggressiveness, worse survival rate of patients and better prognostic effect of chemotherapy. The importance of determining the level of Ki-67 for assessment of tumor aggressiveness was revealed. Significant differences in receptor status of the primary tumor and metastases were proven. Data on the impact of changes in receptor status of the tumor prognosis are ambiguous and need further study. The use of targeted agents in the treatment of HER2 + patients can significantly improve treatment outcomes, turning this MS from historically aggressive subgroup to quite favorable. |
| format | Article |
| id | doaj-art-c45480f8a0db463e813adb97c4794fee |
| institution | Kabale University |
| issn | 2307-0404 2307-0404 |
| language | English |
| publishDate | 2016-05-01 |
| publisher | Dnipro State Medical University |
| record_format | Article |
| series | Medičnì Perspektivi |
| spelling | doaj-art-c45480f8a0db463e813adb97c4794fee2024-12-02T09:48:31ZengDnipro State Medical UniversityMedičnì Perspektivi2307-04042307-04042016-05-012128186The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancerBondarenko I.N.0Elhajj Mohammad H.1Chebanov K.O.2Phokhach A.V.3Bondarenko Y.N. 4SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine» SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine» ME «Dnipropetrovsk City Multidisciplinary Hospital N 4» DRCSE «Dnipropetrovsk medical academy of Health Ministry of Ukraine» SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine» Extreme heterogeneity of breast cancer (BC) is considered to be one of the reasons that affects the success of treatment. According to current classifications, there are 4 molecular subtypes (MS). The basis for subtypes division is immunohistochemical testing of tumor cell receptors - estrogen (ER), progesterone (PR), HER2-neu and Ki-67. The doctrine of the tumor MS was the basis for the individualization of therapeutic tactics in patients with breast cancer. It was studied that luminal A subtype is the most common and the most favorable, with hormone therapy being a highly effective treatment method. Luminal B subtype, HER2 - positive and triple negative MS is characterized by a high aggressiveness, worse survival rate of patients and better prognostic effect of chemotherapy. The importance of determining the level of Ki-67 for assessment of tumor aggressiveness was revealed. Significant differences in receptor status of the primary tumor and metastases were proven. Data on the impact of changes in receptor status of the tumor prognosis are ambiguous and need further study. The use of targeted agents in the treatment of HER2 + patients can significantly improve treatment outcomes, turning this MS from historically aggressive subgroup to quite favorable.http://medpers.dsma.dp.ua/issues/2016/N2/81-86.pdfbreast cancermolecular subtypeheterogeneityindividualizationimmunohistochemical testing |
| spellingShingle | Bondarenko I.N. Elhajj Mohammad H. Chebanov K.O. Phokhach A.V. Bondarenko Y.N. The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer Medičnì Perspektivi breast cancer molecular subtype heterogeneity individualization immunohistochemical testing |
| title | The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer |
| title_full | The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer |
| title_fullStr | The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer |
| title_full_unstemmed | The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer |
| title_short | The role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer |
| title_sort | role of tumor molecular subtypes in formation of personalized approach to the theatment of the breast cancer |
| topic | breast cancer molecular subtype heterogeneity individualization immunohistochemical testing |
| url | http://medpers.dsma.dp.ua/issues/2016/N2/81-86.pdf |
| work_keys_str_mv | AT bondarenkoin theroleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT elhajjmohammadh theroleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT chebanovko theroleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT phokhachav theroleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT bondarenkoyn theroleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT bondarenkoin roleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT elhajjmohammadh roleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT chebanovko roleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT phokhachav roleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer AT bondarenkoyn roleoftumormolecularsubtypesinformationofpersonalizedapproachtothetheatmentofthebreastcancer |